Physician profile
Zoheir Ahmad Abdelbaki
NPI 1396818571
$5,708.08
in general payments reported to CMS, 2019-2025
41 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $1,243 · 2021: $1,059 · 2022: $981 · 2023: $649 · 2024: $345 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096 · Education: $44.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.16 |
| Education | $44.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $694.17 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $558.06 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $554.87 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $487.58 | 2019-2025 | Lifevest |
| Astellas Pharma US INC | $414.74 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.60 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $323.97 | 2019-2024 | Andexxa |
| Merck Sharp & Dohme LLC | $235.24 | 2021-2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $206.95 | 2020-2023 | Uptravi, Opsumit |
| Philips North America LLC | $199.26 | 2020-2025 | (Ck4) Mcot, Mcot |
| Amarin Pharma, INC. | $190.93 | 2019-2022 | |
| Abbott Laboratories | $181.31 | 2020-2023 | Cardiomems |
| Pfizer INC. | $154.24 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $112.35 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $104.04 | 2019-2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $103.43 | 2022-2023 | Camzyos, Eliquis |
| Atricure, INC. | $88.47 | 2022-2023 | |
| Cvrx, INC. | $79.42 | 2024 | Barostim Neo System |
| Boston Scientific Corporation | $78.59 | 2020-2025 | Watchman Access System, Cds - Mct/Cem Monitoring |
| Esperion Therapeutics, INC. | $61.61 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.50 | 2021-2023 | |
| Cardiovascular Systems INC. | $49.28 | 2019-2020 | |
| Lundbeck LLC | $46.25 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $44.17 | 2020-2022 | |
| Chiesi USA, INC. | $37.28 | 2019 | |
| Novo Nordisk INC | $31.53 | 2023 | Ozempic |
| Lexicon Pharmaceuticals, INC. | $31.16 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $29.87 | 2023 | Optimizer |
| Abiomed | $28.58 | 2019-2024 | Impella |
| Gilead Sciences, INC. | $24.40 | 2019 | |
| Recor Medical INC | $24.21 | 2025 | Paradise Ultrasound Renal Denervation System |
| Terumo Medical Corporation | $20.10 | 2023 | Glidesheath Slender |
| Avinger INC. | $17.35 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.34 | 2019 | |
| W. L. Gore & Associates, INC. | $15.22 | 2019 | |
| Baxter Healthcare | $14.88 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Angiodynamics, INC. | $14.06 | 2019 | |
| Daiichi Sankyo INC. | $12.86 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.69 | 2021 | |
| Thrombolex, INC. | $12.25 | 2024 | Bashir Endovascular Catheter |
| Heartflow, INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoheir Abdelbaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.